Adtran FSP 3000 OLS plays key role in OIF’s largest-ever demo at OFC
22.3.2024 16:00:00 EET | Business Wire | Press release
Adtran today announced that it’s playing a key role in the Optical Internetworking Forum’s (OIF) most extensive multi-vendor interoperability demo to date, held at the Optical Fiber Communication Conference and Exhibition (OFC). Central to the showcase is Adtran’s FSP 3000 open line system (OLS), which delivers 400Gbit/s OpenZR+ transceiver interoperability across a 1,000km link. The OLS features advanced automation and optimization for maximum performance and user-friendly operation. Involving 47 member companies, the demo marks a major milestone in open networking and highlights the commitment of the OIF community to driving the future of high-performance, efficient and scalable network solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240322753779/en/
Adtran’s FSP 3000 OLS is playing a central role in the OIF’s biggest interoperability demo to date. (Photo: Business Wire)
“Interoperability continues to be at the heart of our vision for the future of optical networking. This year, by showcasing our FSP 3000 OLS’s capacity for 400Gbit/s OpenZR+ transceiver interoperability over regional distances, we’re pushing the boundaries of end-to-end network performance,” said Stephan Neidlinger, VP of global business development at Adtran. “Together with our fellow industry innovators at the OIF, we’re spotlighting what can be achieved when we unite behind intelligent, open architectures. This shared dedication to supporting multi-vendor environments will ensure superior network performance and new levels of flexibility for our customers.”
The demo uses Adtran’s FSP 3000 OLS to interconnect 400Gbit/s OpenZR+ pluggable transceivers from different suppliers over a bidirectional link that extends up to 1,000km. This comprises eight spans and utilizes Corning’s SMF-28 ULL and Contour fibers. The setup uses compact amplification modules integrating EDFA and Raman amplification, OSC, monitor ports and auto-span equalization. This enables an OLS configuration with a high degree of integration, performance, automation and ease of use. It also features terminal nodes with flexible multi-degree ROADMs for power equalization and scalability. The configuration provides an open hardware platform with programmable interfaces that pave the way for interoperability across various data rates, modulation formats and upgrades to 800Gbit/s transport.
“This demo is a testament to the power of strategic collaboration and technological integration, epitomizing the core principles our FSP 3000 OLS was built upon: openness, scalability and cutting-edge performance. Through concerted efforts with our OIF partners, from renowned component manufacturers to key industry players, we’re crafting solutions that will provide the adaptability and optical prowess our customers need for the networking challenges they face,” commented Ryan Schmidt, GM of optical transport at Adtran. “By focusing on customized solutions and embracing an ecosystem-wide approach, Adtran is not only tackling current network complexities but also setting the stage for future advancements, ensuring that our customers will always stay ahead of the game.”
About the OIF demo
OIF to Showcase Interoperability at OFC 2024 with Nearly 50 Member Companies Collaborating to Address Unprecedented Demand for Next-Generation Network Solutions.
OIF’s interoperability demonstration at OFC 2024 will feature 47 member companies showcasing breakthrough solutions in speed, power and density to meet the growing demands of next-generation data center networking, AI/ML and disaggregation applications. See the solutions in 800ZR, 400ZR and OpenZR+ optics, Energy Efficient Interfaces (EEI) & Co-Packaging, Common Electrical I/O (CEI) channels and Common Management Interface Specification (CMIS) implementations that are playing a pivotal role in shaping the industry for the next decade. Experience these live and interactive demonstrations at booth #1323. For more information, visit: www.oiforum.com/meetings-events/oif-ofc-2024.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322753779/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
